Navigation Links
Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market
Date:11/19/2008

However, Generic Erosion and a Dearth of Promising Emerging Therapies Will Result in Modest Annual Growth, According to a New Report from Decision Resources

WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to their improvements in safety and efficacy, physicians are increasingly prescribing next-generation antifungals such as Pfizer's Vfend, Schering-Plough's Noxafil, Merck's Cancidas, Astellas' Mycamine and Pfizer's Eraxis. Following the recent launches of several next-generation azoles (such as Vfend and Noxafil) and echinocandins (such as Cancidas, Mycamine and Eraxis), the severe fungal infections market has become increasingly competitive.

The new Pharmacor report entitled Severe Fungal Infections finds that market competition will continue to intensify and the generic erosion of key agents and a dearth of promising emerging therapies will limit growth to a modest two percent annually from 2007 to 2017 in the severe fungal infections drug market. The report also finds that no new products other than Basilea's isavuconazole are expected to generate significant sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan through 2017.

"Interviewed physicians regard isavuconazole as a highly promising new antifungal, and we forecast the agent to be an important driver in the severe fungal infection market through 2017," said Jose Avalos, Ph.D., analyst at Decision Resources. "Isavuconazole provides a favorable spectrum of activity and safety and is likely to be available as both an oral and intravenous therapy. This agent will compete with other marketed drugs in its class and its sales will help offset the declines due to patent expiries of key brands over the next 10 years."

About Severe Fungal Infections

In 2007, severe fungal infections treatments generated more than $1 billion in sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The market for severe fungal infections is highly complex due to the heterogeneous patient populations, risk groups, and pathogens involved. Although five major antifungal products have launched in recent years, the current pipeline remains sparse despite significant remaining unmet need.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources         Decision Resources, Inc.
    Christopher Comfort        Elizabeth Marshall
    781-296-2597               781-296-2563
    ccomfort@dresources.com    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016
2. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
3. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
4. Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008.
5. Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers
6. Researchers find roadmap to next-generation cancer therapies
7. Fourth Annual Games for Health Conference Joins Health and Gaming Innovators to Discuss Next-Generation Game Technologies and Health Issues
8. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
9. iCAD Introduces Next-Generation TotalLook Film Digitizer
10. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
11. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
Breaking Medicine Technology: